Linked Life Data

4042078

Source:http://linkedlifedata.com/resource/pubmed/id/4042078

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1985-11-13
pubmed:abstractText
The effects of a new benzodiazepine derivative, ethyl loflazepate (CM6912), on the arousal level of normal male human subjects were investigated by use of the averaged photopalpebral reflex (PPR), the latency of which is sensitively prolonged with the lowering of the arousal level. Four doses of ethyl loflazepate, i.e., 2 mg, 4 mg, 6 mg, and 8 mg, and a placebo were administered to each subject 30 min after lunch according to a double-blind, crossover design. Ethyl loflazepate prolonged both latencies of PPR in a dose-dependent manner. The dose-response curves for both latencies, derived from the maximum prolongation, showed a definite and linear dose-response relationship. The drug action occurred within 1 h, peaked at 2.5-3 h, and continued slightly even 4 h after medication. In the subjective assessments, vagueness of thought, sleepiness, and weakness were only slightly observed. These results suggest that ethyl loflazepate could be a potent hypnotic and/or anxiolytic which possesses a relatively rapid onset of action with moderate duration and has no severe side effects.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0362-5664
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
271-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Effects of a new benzodiazepine derivative, ethyl loflazepate (CM6912), on the arousal level of normal humans assessed by the averaged photopalpebral reflex.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial